User profiles for MARIE ALT

Marie T. Alt

PhD Student, Department of Microsystems Engineering
Verified email at imtek.de
Cited by 210

Treatment algorithms based on tumor molecular profiling: the essence of precision medicine trials

…, A Vincent-Salomon, N Servant, M Alt… - Journal of the …, 2016 - academic.oup.com
With the advent of high-throughput molecular technologies, several precision medicine (PM)
studies are currently ongoing that include molecular screening programs and PM clinical …

Immunotherapy in head and neck cancers: a new challenge for immunologists, pathologists and clinicians

S Outh-Gauer, M Alt, C Le Tourneau, J Augustin… - Cancer Treatment …, 2018 - Elsevier
Cancer occurrence can be understood as the result of dysfunctions in immune tumoral
microenvironment. Here we review the recent understandings of those microenvironment changes…

Enfortumab Vedotin in urothelial cancer

M Alt, C Stecca, S Tobin, DM Jiang… - … advances in urology, 2020 - journals.sagepub.com
The treatment landscape for metastatic urothelial cancer (mUC) beyond first-line platinum-based
chemotherapy has changed significantly over the last 5 years with the recent approvals …

Hybrid surface design for robust superhydrophobicity

S Dash, MT Alt, SV Garimella - Langmuir, 2012 - ACS Publications
Surfaces may be rendered superhydrophobic by engineering the surface morphology to
control the extent of the liquid–air interface and by the use of low-surface-energy coatings. The …

First-in-human phase I study of single-agent vanucizumab, a first-in-class bispecific anti-angiopoietin-2/anti-VEGF-A antibody, in adult patients with advanced solid …

…, V Boni, A Taus, J Albanell, MP Sablin, M Alt… - Clinical Cancer …, 2018 - AACR
Purpose: Vanucizumab is an investigational antiangiogenic, first-in-class, bispecific mAb
targeting VEGF-A and angiopoietin-2 (Ang-2). This first-in-human study evaluated the safety, …

Let there be light—optoprobes for neural implants

MT Alt, E Fiedler, L Rudmann, JS Ordonez… - Proceedings of the …, 2016 - ieeexplore.ieee.org
Over the past decades, optical technologies have entered neural implant technologies.
Applications such as optogenetics, near-infrared spectroscopy (NIRS), and direct-near-infrared …

[HTML][HTML] Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie

C Basse, C Morel, M Alt, MP Sablin, C Franck… - ESMO open, 2018 - Elsevier
Background High throughput molecular screening techniques allow the identification of multiple
molecular alterations, some of which are actionable and can be targeted by molecularly …

[HTML][HTML] Recent advances in the management of penile cancer: a contemporary review of the literature

CE Stecca, M Alt, DM Jiang, P Chung, JM Crook… - Oncology and …, 2021 - Springer
Penile cancer is a rare condition, which mostly affects men in their sixth decade of life. The
most common histology is squamous cell carcinoma (SCC), with about half of the cases …

Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell …

…, F Rolland, M Chausson, E Borcoman, M Alt… - Investigational new …, 2021 - Springer
Background The phosphatidylinositol-3 kinase pathway is often altered in head and neck
squamous cell carcinoma (HNSCC), and is involved in the resistance to EGFR inhibitors. …

[HTML][HTML] The spectrum of clinical trials aiming at personalizing medicine

C Le Tourneau, M Kamal, M Alt… - Chinese clinical …, 2014 - cco.amegroups.org
All anticancer molecularly targeted agents on the market today have been approved with
one or no companion diagnostic based on a specific genomic molecular alteration. These …